Oxaprozin

Oxaprozin
Clinical data
Trade names	Daypro, Dayrun, Duraprox, others
AHFS/Drugs.com	Monograph
MedlinePlus	a693002
Pregnancy; category	C;
Routes of; administration	By mouth
ATC code	M01AE12 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNING; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	95%
Protein binding	99%
Metabolism	Liver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites.
Elimination half-life	54.9 hours
Identifiers
	IUPAC name 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid;
CAS Number	21256-18-8 ;
PubChem CID	4614;
IUPHAR/BPS	7252;
DrugBank	DB00991 ;
ChemSpider	4453 ;
UNII	MHJ80W9LRB;
KEGG	D00463 ;
ChEBI	CHEBI:7822 ;
ChEMBL	ChEMBL1071 ;
CompTox Dashboard (EPA)	DTXSID1045118 ;
ECHA InfoCard	100.040.254
Chemical and physical data
Formula	C18H15NO3
Molar mass	293.322 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCc1nc(c(o1)c2ccccc2)c3ccccc3;
	InChI InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21) ; Key:OFPXSFXSNFPTHF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID),^[2] used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.

It was patented in 1967 and approved for medical use in 1983.^[3]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI (March 1985). "Oxaprozin pharmacokinetics in the elderly". British Journal of Clinical Pharmacology. 19 (3): 373–378. doi:10.1111/j.1365-2125.1985.tb02656.x. PMC 1463728. PMID 3986088.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[pmid3986088-2] Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI (March 1985). "Oxaprozin pharmacokinetics in the elderly". British Journal of Clinical Pharmacology. 19 (3): 373–378. doi:10.1111/j.1365-2125.1985.tb02656.x. PMC 1463728. PMID 3986088.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 520. ISBN 9783527607495.

[1]

[2]

[3]